{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:34:03Z","timestamp":1772789643760,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pan.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T14:22:46Z","timestamp":1595946166000},"page":"1519-1525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-3722","authenticated-orcid":false,"given":"Noritoshi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Omae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-2234","authenticated-orcid":false,"given":"Yosuke","family":"Horita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-1885","authenticated-orcid":false,"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-2135","authenticated-orcid":false,"given":"Shin","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2020.07.006_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Canc J Clin"},{"key":"10.1016\/j.pan.2020.07.006_bib2","author":"National Cancer Institute Surveillance"},{"key":"10.1016\/j.pan.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"5","author":"Burris","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2020.07.006_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/14656566.2017.1369955","article-title":"Second line treatment options for pancreatic cancer","volume":"18","author":"Passero","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pan.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2020.07.006_bib9","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: A randomized phase III study of fluorouracil\/leucovorin with without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2020.07.006_bib11","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.pan.2020.07.006_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MPA.0000000000001513","article-title":"Clinical practice guideline for pancreatic cancer 2019 from the Japan pancreas society","volume":"49","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2020.07.006_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MPA.0000000000001049","article-title":"Nationwide multicenter observational study of FOLFIRINOX chemotherapy in 399 patients with unresectable or recurrent pancreatic cancer in Japan","volume":"47","author":"Todaka","year":"2018","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2020.07.006_bib14","series-title":"National Cancer Institute Common Terminology criteria for adverse events (CTCAE) v4.03","year":"2010"},{"key":"10.1016\/j.pan.2020.07.006_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.pan.2020.07.006_bib16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2020.07.006_bib17","first-page":"1","article-title":"Randomised phase II study of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer","volume":"103","author":"Ohkawa","year":"2015","journal-title":"Br J Canc"},{"key":"10.1016\/j.pan.2020.07.006_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/annonc\/mdv603","article-title":"A\u00a0randomised phase II study of S-1 plus oral leucovorinversus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"27","author":"Ueno","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2020.07.006_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/bjc.2016.436","article-title":"Randomized phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer","volume":"116","author":"Ioka","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.pan.2020.07.006_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/bjc.2016.185","article-title":"Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer","volume":"115","author":"Chiorean","year":"2016","journal-title":"Br J Canc"},{"key":"10.1016\/j.pan.2020.07.006_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000337225","article-title":"A\u00a0phase I study of infusion 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1:1\/\u22171:1\/\u22176 or \u22171\/\u221728","volume":"82","author":"Sunakawa","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.pan.2020.07.006_bib22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizmab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase II trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pan.2020.07.006_bib23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/cas.13883","article-title":"Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIIRNOX","volume":"110","author":"Shirasu","year":"2019","journal-title":"Canc Sci"},{"key":"10.1016\/j.pan.2020.07.006_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A\u00a0phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Canc Chemother Pharmacol"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390320302210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390320302210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:10:38Z","timestamp":1761408638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390320302210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1424390320302210"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2020.07.006","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}